Therapeutic antagonists and conformational regulation of integrin function

Nature Reviews Drug Discovery

Volumn 2, Issue 9, 2003, Pages 703-716

  Shimaoka, Motomu ^a   Springer, Timothy A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10,11 DIHYDRO 3 [3 (2 PYRIDINYLAMINO)PROPOXY] 5H DIBENZO[A,D]CYCLOHEPTENE 10 ACETIC ACID; A 286982; ABCIXIMAB; ALPHA5 INTEGRIN; BETA INTERMEDIN; BIRT 0377; CELL RECEPTOR; DISINTEGRIN; ECHISTATIN; EPTIFIBATIDE; FIBRINOGEN; INTEGRIN; INTEGRIN RECEPTOR; L 736622; LAMIFIBAN; LFA 703; LIGAND; MONOCLONAL ANTIBODY; RECEPTOR BLOCKING AGENT; RO 44 9833; ROXIFIBAN; TIROFIBAN; UNCLASSIFIED DRUG; XVA 143; NEW DRUG;

ANGIOGENESIS; CELL COMMUNICATION; CELL MEMBRANE; CLINICAL TRIAL; CROHN DISEASE; DEVELOPMENT; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG STRUCTURE; EXTRACELLULAR MATRIX; HEMOSTASIS; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FAMILY; PROTEIN FUNCTION; REACTION ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TISSUE REPAIR; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; METABOLISM;

ANIMALS; DRUGS, INVESTIGATIONAL; HUMANS; INTEGRINS;

EID: 0142026204     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1174     Document Type: Review

References (111)

1. Hynes, R. O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 11-25 (1992).
2. Springer, T. A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multi-step paradigm. Cell 76, 301-314 (1994).
3. Humphries, M. J. Integrin structure. Biochem. Soc. Trans. 28, 311-339 (2000).
4. Shimaoka, M., Takagi, J. & Springer, T. A. Conformational regulation of integrin structure and function. Annu. Rev. Biophys. Biomol. Struct. 31, 485-516 (2002).
5. Curley, G. P., Blum, H. & Humphries, M. J. Integrin antagonists. Cell. Mol. Life Sci. 56, 427-441 (1999).
6. Scarborough, R. M. & Gretler, D. D. Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J. Med. Chem. 43, 3453-3473 (2000).
7. Varner, J. A. & Cheresh, D. A. Tumor angiogenesis and the role of vascular cell integrin αvβ3. Important Adv. Oncol. 69-87 (1996).
8. Giblin, P. A. & Kelly, T A. Antagonists of β2 integrin-mediated cell adhesion. Annu. Rep. Med. Chem. 36, 181-190 (2001).
9. Yusuf-Makagiansar, H., Anderson, M. E., Yakovleva, T. V., Murray, J. S. & Siahaan, T. J. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med. Res. Rev. 22, 146-167 (2002).
10. Bennett, J. S. Novel platelet inhibitors. Annu. Rev. Med. 52, 161-184 (2001).
11. Cather, J. C. & Menter, A. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin. Biol. Ther. 3, 361-370 (2003).
12. Harlan, J. M. & Winn, R. K. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit. Care Med. 30, S214-S219 (2002).
13. Harlan, J. M., Winn, R. K., Vedder, N. B., Doerschulk, C. M. & Rice, C. L. in Adhesion: Its Role in Inflammatory Disease (eds Harlan, J. R. & Liu, D.) 117-150 (W. H. Freeman, New York, 1992).
14. Jackson, D. Y. α4 integrin antagonists. Curr. Pharm. Des. 8, 1229-1253 (2002).
15. Lin, K. C. & Castro, A. C. Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr. Opin. Chem. Biol. 2, 453-457 (1998).
16. Liu, G. Inhibitors of LFA-1/ICAM-1 interaction: from monoclonal antibodies to small molecules. Drugs Future 26, 767-778 (2001).
17. Tilley, J. W., Chen, L., Sidduri, A. & Fotouhi, N. The discovery of VLA-4 antagonists. Curr. Med. Chem. Rev. (in the press).
18. Xiong, J.-P et al. Crystal structure of the extracellular segment of integrin αVβ. Science 294, 339-345 (2001).
19. Beglova, N., Blacklow, S. C., Takagi, J. & Springer, T. A. Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nature Struct. Biol. 9, 282-287 (2002).
20. Du, X. et al. Long range propagation of conformational changes in integrin αIIbβ3. J. Biol. Chem. 268, 23087-23092 (1993).
21. Takagi, J., Erickson, H. P. & Springer, T. A. C-terminal opening mimics 'inside-out' activation of integrin α5β1. Nature Struct. Biol. 8, 412-416 (2001).
22. Weisel, J. W., Nagaswami, C., Vilaire, G. & Bennett, J. S. Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy J. Biol. Chem. 267, 16637-16643 (1992).
23. Takagi, J., Petre, B. M., Walz, T. & Springer, T. A. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 110, 599-611 (2002).
24. Luo, B.-H., Springer, T. A. & Takagi, J. Stabilizing the open conformation of the integrin headpiece with a glycan wedge increases affinity for ligand. Proc. Natl Acad. Sci. USA 100, 2403-2408 (2003).
25. Lee, J.-O., Rieu, P, Arnaout, M. A. & Liddington, R. Crystal structure of the A domain from the a subunit of integrin CR3 (CD11b/CD18). Cell 80, 631-638 (1995).
26. Huang, C., Zang, Q., Takagi, J. & Springer, T. A. Structural and functional studies with antibodies to the integrin β2 subunit: a model for the I-like domain. J. Biol. Chem. 275, 21514-21524 (2000).
27. Springer, T. A. Folding of the N-terminal, ligand-binding region of integrin α-subunits into a β-propeller domain. Proc. Natl Acad. Sci. USA 94, 65-72 (1997).
28. Diamond, M. S., Garcia-Aguilar, J., Bickford, J. K., Corbi, A. L. & Springer, T. A. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J. Cell Biol. 120, 1031-1043 (1993).
29. Michishita, M., Videm, V. & Arnaout, M. A. A novel divalent cation-binding site in the A domain of the β2 integrin CR3 (CD11b/CD18) is essential for ligand binding. Cell 72, 857-867 (1993).
30. Shimaoka, M., Lu, C., Palframan, R., von Andrian, U. H., Takagi, J. & Springer, T. A. Reversibly locking a protein fold in an active conformation with a disulfide bond: integrin αL I domains with high affinity and antagonist activity in vivo. Proc. Natl Acad. Sci. USA 98, 6009-6014 (2001).
31. Huth, J. R. et al. NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding. Proc. Natl Acad. Sci. USA 97, 5231-5236 (2000).
32. Shimaoka, M. et al. Structures of the αL I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 112, 99-111 (2003).
33. Emsley, J., Knight, C. G., Farndale, R. W., Barnes, M. J. & Liddington, R. C. Structural basis of collagen recognition by integrin α2β1. Cell 101, 47-56 (2000).
34. Takagi, J., Kamata, T, Meredith, J., Puzon-McLaughlin, W. & Takada, Y. Changing ligand specificities of αvβ1 and αvβ3 integrins by swapping a short diverse sequence of the β subunit. J. Biol. Chem. 272, 19794-19800 (1997).
35. Xiong, J. P et al. Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. Science 296, 151-155 (2002).
36. Takagi, J. & Springer, T. A. Integrin activation and structural rearrangement. Immunological Rev. 186, 141-163 (2002).
37. Puzon-McLaughlin, W., Kamata, T. & Takada, Y. Multiple discontinuous ligand-mimetic antibody binding sites define a ligand binding pocket in integrin αIIbβ3. J. Biol. Chem. 275, 7795-7802 (2000).
38. Kamata, T., Tieu, K. K., Springer, T. A. & Takada, Y. Amino acid residues in the αIIb subunit that are critical for ligand binding to integrin αIIbβ3 are clustered in the β-propeller model. J. Biol. Chem. 276, 44275-44283 (2001).
39. Luo, B.-H., Springer, T. A. & Takagi, J. High affinity ligand binding by integrins does not involve head separation. J. Biol. Chem. 178, 17185-17189 (2003).
40. Lu, C., Shimaoka, M., Ferzly, M., Oxvig, C., Takagi, J. & Springer, T. A. An isolated, surface-expressed I domain of the integrin αLβ2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide. Proc. Natl Acad. Sci. USA 98, 2387-2392 (2001).
41. Lu, C., Shimaoka, M., Zang, Q., Takagi, J. & Springer, T. A. Locking in alternate conformations of the integrin αLβ2 I domain with disulfide bonds reveals functional relationships among integrin domains. Proc. Natl Acad. Sci. USA 98, 2393-2398 (2001).
42. Alonso, J. L., Essafi, M., Xiong, J. P., Stehle, T. & Arnaout, M. A. Does the integrin αA domain act as a ligand for its βA domain? Curr. Biol. 12, R340-R342 (2002).
43. Sales, A., Shimaoka, M., Chen, S., Carman, C. V. & Springer, T. A. Transition from rolling to firm adhesion is regulated by the conformation of the I domain of the integrin LFA-1. J. Biol. Chem. 277, 50255-50262 (2002).
44. Dustin, M. L. & Springer, T. A. T cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 341, 619-624 (1989).
45. Lollo, B. A., Chan, K. W. H., Hanson, E. M., Moy, V. T. & Brian, A. A. Direct evidence for two affinity states for lymphocyte function-associated antigen 1 on activated T cells. J. Biol. Chem. 268, 21693-21700 (1993).
46. Constantin, G. et al. Chemokines trigger immediate β2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity 13, 759-769 (2000).
47. Vinogradova O. et al. A structural mechanism of integrin αIIbβ3 'inside-out' activation as regulated by its cytoplasmic face. Cell 110, 587-597 (2002).
48. Lu, C., Takagi, J. & Springer, T. A. Association of the membrane-proximal regions of the α and β subunit cytoplasmic domains constrains an integrin in the inactive state. J. Biol. Chem. 276, 14642-14648 (2001).
49. Kim, M., Carman, C. V. & Springer, T. A. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science (in the press).
50. Bednar, R. A. et al. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets. J. Pharmacol. Exp. Ther. 285, 1317-1326 (1998).
51. Duggan, M. E. et al. Nonpeptide αVβ3 antagonists. 1. Transformation of a potent, integrin-selective αIIbβ3 antagonist into a potent αVβ3 antagonist. J. Med. Chem. 43, 3736-3745 (2000).
52. Shin, D. T., Edelman, J. M., Horwitz, A. F., Grunwald, G. B. & Buck, C. A. Structure/function analysis of the integrin β1 subunit by epitope mapping. J. Cell Biol. 122, 1361-1371 (1993).
53. Bazzoni, G., Shin, D.-T, Buck, C. A. & Hemler, M. A. Monoclonal antibody 9EG7 defines a novel β1 integrin epitope induced by soluble ligand and manganese, but inhibited by calcium. J. Biol. Chem. 270, 25570-25577 (1995).
54. Takagi, J., Isobe, T., Takada, Y. & Saito, Y. Structural interlock between ligand-binding site and stalk-like region of β1 integrin revealed by a monoclonal antibody recognizing conformation-dependent epitope. J. Biochem. (Tokyo) 121, 914-921 (1997).
55. Lu, C., Ferzly, M., Takagi, J. & Springer, T. A. Epitope mapping of antibodies to the C-terminal region of the integrin β2 subunit reveals regions that become exposed upon receptor activation. J. Immunol. 166, 5629-5637 (2001).
56. Du, X. et al. Ligands 'activate' integrin αIIbβ3 (platelet GPIIb-IIIa). Cell 65, 409-416 (1991).
57. Kouns, W. C. at al. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood 80, 2539-2547 (1992).
58. 2+ signaling. Blood 92, 3675-3683 (1998).
59. Muller, B., Zerwes, H. G., Tangemann, K., Peter, J. & Engel, J. Two-step binding mechanism of fibrinogen to αIIbβ3 integrin reconstituted into planar lipid bilayers. J. Biol. Chem. 268, 6800-6808 (1993).
60. Huber, W. et al. Determination of kinetic constants for the interaction between the platelet glycoprotein IIb-IIIa and fibrinogen by means of surface plasmon resonance. Eur. J. Biochem. 227, 647-656 (1995).
61. Bednar, B. et al. Flow cytometric measurement of kinetic and equilibrium binding parameters of arginine-glycine-aspartic acid ligands in binding to glycoprotein IIb/IIIa on platelets. Cytometry 28, 58-65 (1997).
62. Murphy, N. P., Pratico, D. & Fitzgerald, D. J. Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo. J. Pharmacol. Exp. Ther. 286, 945-951 (1998).
63. Thibault, G. Sodium dodecyl sulfate-stable complexes of echistatin and RGD-dependent integrins: a novel approach to study integrins. Mol. Pharmacol. 58, 1137-1145 (2000).
64. Thibault, G., Tardif, P. & Lapalme, G. Comparative specificity of platelet αIIbβ3 integrin antagonists. J. Pharmacol. Exp. Ther. 296, 690-696 (2000).
65. Zolotarjova, N. I., Hollis, G. F. & Wynn, R. Unusually stable and long-lived ligand-induced conformations of integrins. J. Biol. Chem. 276, 17063-17068 (2001).
66. Billheimer, J. T. et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 99, 1-7 (2002).
67. Peter, K., Schwarz, M., Nordt, T. & Bode, C. Intrinsic activating properties of GP IIb/IIIa blockers. Thromb. Res. 103, S21-S27 (2001).
68. Frelinger, A. L., Furman, M. I., Krueger, L. A., Bernard, M. R. & Michelson, A. D. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation 104, 1374-1379 (2001).
69. Schneider, D. J., Taatjes, D. J. & Sobel, B. E. Paradoxical inhibition of fibrinogen binding and potentiation of α-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc. Res. 45, 437-446 (2000).
70. Brown, E. J. & Gresham, R. D. in Structure, Function, and Regulation of Molecules Involved in Leukocyte Adhesion Vol. 1 (eds Lipsky, P. E., Rothlein, R., Kishimoto, T. K., Faanes, R. B. & Smith, C. W.) 78-91 (Springer, New York, 1993).
71. Varner, J. A. & Cheresh, D. A. Integrins and cancer Curr. Opin. Cell Biol. 8, 724-730 (1996).
72. Hynes, R. O. A reevaluation of integrins as regulators of angiogenesis. Nature Med. 8, 918-921 (2002).
73. Engleman, V. W. et al. A peptidomimetic antagonist of the αVβ3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J. Clin. Invest. 99, 2284-2292 (1997).
74. Bach, A. C. et al. Type II to type 1β-turn swap changes specificity for integrins. J. Am. Chem. Soc. 118, 293-294 (1996).
75. Bazzoni, G. & Hemler, M. E. Are changes in integrin affinity and conformation overemphasized? Trends Biochem. Sci. 23, 30-34 (1998).
76. Honda, S. et al. Ligand binding to integrin αvβ3 requires tyrosine 178 in the αv subunit. Blood 97, 175-182 (2001).
77. Legler, D. F., Wiedle, G., Ross, F. F. & Imhof, B. A. Superactivation of integrin αVβ3 by low antagonist concentrations. J. Cell Sci. 114, 1545-1553 (2001).
78. Hynes, R. O. Integrins: bi-directional, allosteric, signalling machines. Cell 110, 673-687 (2002).
79. Yednock, T. A. et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 356, 63-66 (1992).
80. Miller, D. H. et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15-23 (2003).
81. Ghosh, S. et al. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348, 24-32 (2003).
82. Butcher, E. C. & Picker, L. J. Lymphocyte homing and homeostasis. Science 272, 60-66 (1996).
83. Wang, J.-H. & Springer, T. A. Structural specializations of immunoglobulin superfamily members for adhesion to integrins and viruses. Immunol. Rev. 163, 197-215 (1998).
84. Copie, V. et al. Solution structure and dynamics of linked cell attachment modules of mouse fibronectin containing the RGD and synergy regions: comparison with the human fibronectin crystal structure. J. Mol. Biol. 277, 663-682 (1998).
85. Chen, L. L. et al. Identification of ligand binding sites on integrin α4β1 through chemical cross-linking. Biochemistry 37, 8743-8753 (1998).
86. Irie, A., Kamata, T. & Takada, Y. Multiple loop structures critical for ligand binding of the integrin α4 subunit in the upper face of the β-propeller models. Proc. Natl Acad. Sci. USA 94, 7198-7203 (1997).
87. Yednock, T. A. et al. α4β1 integrin-dependent cell adhesion is regulated by a low affinity receptor pool that is conformationally responsive to ligand. J. Biol. Chem. 270, 28740-28750 (1995).
88. 2+ or antibody activation. J. Biol. Chem. 276, 48670-48678 (2001).
89. Dustin, M. L. & Springer, T. A. in Guidebook to the Extracellular Matrix and Adhesion Proteins (eds Kreis, T. & Vale, R.) 228-232 (Sambrook and Tooze, New York, 1999).
90. Grakoui, A. et al. The immunological synapse: a molecular machine controlling T cell activation. Science 285, 221-227 (1999).
91. Gottlieb, A. et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J. Am. Acad. Dermatol. 42, 428-435 (2000).
92. Dustin, M. L. & Springer, T. A. in Guidebook to the Extracellular Matrix and Adhesion Proteins (eds Kreis, T. & Vale, R.) 216-220 (Sambrook and Tooze, New York, 1999).
93. Diamond, M. S., Staunton, D. E., Marlin, S. D. & Springer, T A. Binding of the integrin Mac-1 (CD11b/CD18) to the third Ig-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell 65, 961-971 (1991).
94. Huang, C. & Springer, T. A. A binding interface on the I domain of lymphocyte function associated antigen-1 (LFA-1) required for specific interaction with intercellular adhesion molecule 1 (ICAM-1). J. Biol. Chem. 270, 19008-19016 (1995).
95. Kallen, J. et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J. Mol. Biol. 292, 1-9 (1999).
96. Last-Barney, K. et al. Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein-protein interaction. J. Am. Chem. Soc. 123, 5643-5650 (2001).
97. Liu, G. et al. Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. J. Med. Chem. 44, 1202-1210 (2001).
98. Welzenbach, K., Hommel, U. & Weitz-Schmidt, G. Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of lymphocyte function-associated antigen-1: molecular insights into integrin inhibition. J. Biol. Chem. 277, 10590-10598 (2002).
99. Woska, J. R. Jr et al. A small-molecule antagonist of LFA-1 blocks a conformational change important for LFA-1 function. J. Leukoc. Biol. 70, 329-334 (2001).
100. Shimaoka, M., Salas, A., Yang, W., Weitz-Schmidt, G. & Springer, T. A. Small molecule integrin antagonists that bind to the β2 subunit I-like domain and activate signals in one direction and block them in another. Immunity (in the press).
101. Fotouhi, N., Gillespie, P., Guthrie, R., Pietranico-Cole, S. & Yun, W. Diaminopropionic acid derivatives. PCT Int. Appl. Hoffmann-La Roche, Switzerland, WO0021920 (1999).
102. Burdick, D. J. Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders. PCT Int. Appl. Genentech, USA, WO9949856 (1999).
103. Gadek, T. R. et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science 295, 1086-1089 (2002).
104. Hesterberg, F. E. et al. Rapid resolution of chronic colitis with an antibody to a gut homing integrin α4β7. Gastroenterology 111, 1373-1380 (1996).
105. de Fougerolles, A. R. et al. Regulation of inflammation by collagen-binding integrins α1β1 and α2β1 in models of hypersensitivity and arthritis. J. Clin. Invest. 105, 721-729 (2000).
106. Doolittle, R. F. Fibrinogen and fibrin. Sci. Am. 245, 126-135 (1981).
107. Henschen, A., Lottspeich, F., Kehl, M. & Southan, C. Covalent structure of fibrinogen. Ann. NY Acad. Sci. 408, 28-43 (1983).
108. Springer, T. A. Predicted and experimental structures of integrins and β-propellers. Curr. Opin. Struct. Biol. 12, 802-813 (2002).
109. Coleman, P. J. et al. Non-peptide αVβ3 antagonists. Part 3: identification of potent RGD mimetics incorporating novel β-amino acids as aspartic acid replacements. Bioorg. Med. Chem. Lett. 12, 31-34 (2002).
110. Ward, K. W. et al. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. Drug Metab. Dispos. 27, 1232-1241 (1999).
111. Weitz-Schmidt, G. et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Med. 7, 687-692 (2001).